Aptamer Group lifts H1 revenue 27% as licensing push builds recurring income

Aptamer Group Plc ( (GB:APTA) ) has shared an announcement.

Aptamer Group reported a 27% year-on-year rise in unaudited first-half revenue to £0.83 million, backed by a fee-for-service order book of more than £2.0 million for FY26 and a £3.1 million sales pipeline, giving the board confidence that full-year revenue will materially exceed last year. The Group has accelerated its transition from development to commercialisation, signing non-exclusive licensing deals with Twist Bioscience and Alphazyme that bring immediate payments and future royalties, advancing additional licensing discussions for its Optimer® binders in diagnostics and enzymes, and securing a top-three pharmaceutical partner for radioligand development alongside substantial repeat contracts from other top-tier pharma clients. Progress with Unilever programmes, new Optimer® IHC reagents for a global diagnostics company, and a de-risked fibrotic liver therapeutic candidate collectively strengthen Aptamer’s IP base and validate its dual revenue strategy, positioning the company for higher-margin, recurring income streams and reinforcing its standing as a niche technology partner to blue-chip players across pharma, diagnostics and consumer goods.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Spark’s Take on GB:APTA Stock

According to Spark, TipRanks’ AI Analyst, GB:APTA is a Neutral.

The score is held back primarily by very weak financial performance (sharp revenue decline, ongoing losses, and negative cash flows). Technicals are the main offset, showing a clear uptrend with supportive momentum. Valuation remains constrained by unprofitability and the absence of dividend information.

To see Spark’s full report on GB:APTA stock, click here.

More about Aptamer Group Plc

Aptamer Group plc, listed on AIM, develops next-generation synthetic binders under its Optimer® platform for the life sciences industry, focusing on applications across pharmaceuticals, diagnostics, consumer goods and emerging areas such as radioligand therapies. The company is shifting its model toward higher-margin, recurring revenues through fee-for-service discovery projects and non-exclusive licensing deals that monetise its proprietary technology and intellectual property in global markets.

Average Trading Volume: 7,395,690

Technical Sentiment Signal: Buy

Current Market Cap: £28.32M

See more insights into APTA stock on TipRanks’ Stock Analysis page.